Literature DB >> 6848075

Biologic behavior of thin malignant melanomas with regressive changes.

R R Paladugu, R H Yonemoto.   

Abstract

Thin cutaneous malignant melanomas are defined as lesions measuring less than 0.76 mm in maximal thickness. Eight of the 36 thin lesions that we studied metastasized within two to 120 months. Of the 11 lesions with regressive features, five (45.5%) metastasized. Of 25 lesions without regression, only three (12%) metastasized. Thin melanomas with regressive changes need to be reported as a separate category because of their propensity to metastasize. Conventional prognostic guidelines for treatment of thin melanomas are not applicable to this type of lesion. Clinicians need to be cognizant that regressive changes are serious warning signals when they occur in thin melanomas.

Entities:  

Mesh:

Year:  1983        PMID: 6848075     DOI: 10.1001/archsurg.1983.01390010031008

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  14 in total

1.  The significance of inflammation and regression in melanoma.

Authors:  M G Cook
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1992

Review 2.  Regressing thin cutaneous malignant melanomas (< or = 1.0 mm) are associated with angiogenesis.

Authors:  R L Barnhill; M A Levy
Journal:  Am J Pathol       Date:  1993-07       Impact factor: 4.307

3.  Regression in primary cutaneous melanoma: etiopathogenesis and clinical significance.

Authors:  Phyu P Aung; Priyadharsini Nagarajan; Victor G Prieto
Journal:  Lab Invest       Date:  2017-02-27       Impact factor: 5.662

4.  Outcome of sentinel lymph node biopsy and prognostic implications of regression in thin malignant melanoma.

Authors:  Susannah E McClain; Amber L Shada; Megan Barry; James W Patterson; Craig L Slingluff
Journal:  Melanoma Res       Date:  2012-08       Impact factor: 3.599

5.  Cutaneous melanomas exhibiting unusual biologic behavior.

Authors:  H M Shaw; J K Rivers; S W McCarthy; W H McCarthy
Journal:  World J Surg       Date:  1992 Mar-Apr       Impact factor: 3.352

Review 6.  Melanoma peptide vaccines: from preclinical background to clinical trials.

Authors:  J Weber
Journal:  Curr Oncol Rep       Date:  2000-01       Impact factor: 5.075

7.  Expression of transforming growth factor-beta 2 in malignant melanoma correlates with the depth of tumor invasion. Implications for tumor progression.

Authors:  J A Reed; N S McNutt; V G Prieto; A P Albino
Journal:  Am J Pathol       Date:  1994-07       Impact factor: 4.307

8.  Thin (less than or equal to 1 mm) melanomas of the extremities are biologically favorable lesions not influenced by regression.

Authors:  H J Wanebo; P H Cooper; R W Hagar
Journal:  Ann Surg       Date:  1985-04       Impact factor: 12.969

9.  Clinical features of superficial spreading melanomas with zones of regression.

Authors:  B M Czarnetzki; M Denter; E B Bröcker; P Rümke; V Krieg; F Vakilzadeh; E Macher
Journal:  J Cancer Res Clin Oncol       Date:  1984       Impact factor: 4.553

10.  Lethal "thin" malignant melanoma. Identifying patients at risk.

Authors:  C L Slingluff; R T Vollmer; D S Reintgen; H F Seigler
Journal:  Ann Surg       Date:  1988-08       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.